A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose

by | Feb 12, 2026 | Clinical Trials | 0 comments

​ Conditions: Pneumonia, Bacterial

Interventions: Biological: Pn-MAPS30plus; Combination Product: PCV20

Sponsors: GlaxoSmithKline

Not yet recruiting Conditions: Pneumonia, Bacterial
Interventions: Biological: Pn-MAPS30plus; Combination Product: PCV20
Sponsors: GlaxoSmithKline
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *